20287-70-1

Basic information

• Product Name: 2-(4-chlorophenyl)-4-thiazoleacetic acid ethyl ester
• Synonyms: 2-(4-chlorophenyl)-4-thiazoleacetic acid ethyl ester;ethyl 2-(2-(4-chlorophenyl)thiazol-4-yl)acetate;Ethyl fenclozate
• CAS NO: 20287-70-1
• Molecular Formula: C₁₃H₁₂ClNO₂S
• Molecular Weight: 281.76
• Mol File: 20287-70-1.mol
• Article Data: 10

Chemical Properties

• Melting Point: 114-116℃
• Boiling Point: 400.6°C at 760 mmHg
• Flash Point: 196.1°C
• Appearance: /
• Density: 1.288
• Vapor Pressure: 1.26E-06mmHg at 25°C
• Refractive Index: 1.58
• CAS DataBase Reference: 2-(4-chlorophenyl)-4-thiazoleacetic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-chlorophenyl)-4-thiazoleacetic acid ethyl ester(20287-70-1)
• EPA Substance Registry System: 2-(4-chlorophenyl)-4-thiazoleacetic acid ethyl ester(20287-70-1)

Safety Data

• Hazardous Substances Data: 20287-70-1(Hazardous Substances Data)

Usage

General Description

2-(4-chlorophenyl)-4-thiazoleacetic acid ethyl ester, also known as ethyl 2-(4-chlorophenyl)-4-thiazoleacetate, is a chemical compound with potential pharmaceutical applications. It belongs to the class of thiazole compounds, which have been studied for their antimicrobial, antifungal, and anti-inflammatory properties. This specific compound has been investigated for its potential use in developing new drugs for the treatment of various bacterial and fungal infections, as well as for its potential anti-inflammatory effects. Its ethyl ester form also suggests that it may have improved solubility and pharmacokinetic properties compared to the parent acid, making it a promising candidate for further pharmaceutical development.

InChI:InChI=1/C13H12ClNO2S/c1-2-17-12(16)7-11-8-18-13(15-11)9-3-5-10(14)6-4-9/h3-6,8H,2,7H2,1H3

Upstream product

• 638-07-3 ethyl (2-chloroaceto)acetate 
• 2521-24-6 4-chlorothiobenzamide 
• 64-17-5 ethanol 
• 32807-28-6 Methyl 4-chloroacetoacetate 
• 2521-24-6 4-chlorobenzothioamide 
• 1116-50-3 4-bromo-3-ethoxy-2-butenoic acid ethyl ester 
• 70-23-5 ethyl Bromopyruvate 

Downstream Products

• 58827-73-9 2-[2-(4-Chloro-phenyl)-thiazol-4-yl]-N-{2-[3-(2-cyano-phenoxy)-2-hydroxy-propylamino]-ethyl}-acetamide 
• 17969-36-7 2-[2-(4-chloro-phenyl)-thiazol-4-yl]-acetamide 
• 425381-87-9 ethyl 2-[2-(4-chlorophenyl)thiazol-4-yl]pent-4-enoate 
• 425381-74-4 3-[2-(4-chlorophenyl)thiazol-4-yl]-5-methyltetrahydrofuran-2-one 
• 425381-94-8 2-[2-(4-chlorophenyl)thiazol-4-yl]pent-4-enoic acid 
• 78743-13-2 3-[2-(4-Chloro-phenyl)-thiazol-4-yl]-4-hydroxy-pyrrole-2,5-dione 
• 27473-03-6 2-(2-(4-chlorophenyl)thiazol-4-yl)ethan-1-ol 
• 33313-15-4 [2-(4-chloro-phenyl)-thiazol-4-yl]-acetic acid hydrazide 
• 18832-93-4 2-(2-(4-chlorophenyl)thiazol-4-yl)acetonitrile 

Relevant articles and documents

PROCESS FOR PREPARING A POTENT THIAZOLE COMPOUND, PHARMACEUTICAL FORMULATION AND USES THEREOF

The present invention relates to a process for preparing N-[2-[2-(4-chlorophenyl)-4- thiazolyl] ethyl]-butanamide. The present invention further relates to a pharmaceutical formulation and the use of said pharmaceutical formulation consisting of N-[2-[2-(

Modular synthesis of thiazoline and thiazole derivatives by using a cascade protocol

Thiazolines and thiazoles are an integral part of numerous natural products, a number of drugs, and many useful molecules such as ligands for metal catalysis. We report the first common synthetic protocol for the synthesis of thiazoles and thiazolines. Novel molecules are efficiently synthesized by using readily available and inexpensive substrates. The reaction conditions are mild and pure products are obtained without work-up and column purification.

MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER

Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X1, X2, R1-4 and R13-18 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.